CytoSorbents has filed a patent for a method of removing advanced glycation end products (AGEs) from bodily fluids. The invention involves contacting the bodily fluid with a sorbent to effectively remove these harmful substances. GlobalData’s report on CytoSorbents gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on CytoSorbents, Wearable breast pumps was a key innovation area identified from patents. CytoSorbents's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Method for removing advanced glycation end products from bodily fluid
A recently filed patent (Publication Number: US20230310493A1) describes a method for removing advanced glycation end products (AGEs) from bodily fluids. The method involves contacting the bodily fluid with a sorbent material. The sorbent material has a specific pore structure, ranging from 50 Å to 40,000 Å, with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm. It is also biocompatible, making it safe for use in the body.
The bodily fluid that can be treated using this method includes saliva, nasopharyngeal fluid, blood, plasma, serum, gastrointestinal fluid, bile, cerebrospinal fluid, pericardial fluid, vaginal fluid, seminal fluid, prostatic fluid, peritoneal fluid, pleural fluid, urine, synovial fluid, interstitial fluid, intracellular fluid, extracellular fluid, lymph, mucus, or vitreous humor.
The sorbent material used in the method has a specific pore structure that ensures effective removal of AGEs. The total pore volume of pore sizes ranging from 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g of dry sorbent. Additionally, the ratio of pore volume between 50 Å to 40,000 Å to pore volume between 1,000 Å to 10,000 Å is smaller than 2:1.
The sorbent material is composed of at least one crosslinking agent and at least one monomer. It may also include at least one dispersing agent and at least one porogen. Examples of crosslinking agents include divinylbenzene, trivinylbenzene, and divinylsulfone. Monomers can include divinylbenzene, ethylvinylbenzene, styrene, acrylonitrile, and many others. Dispersing agents can include hydroxyethyl cellulose, poly (hydroxyethyl methacrylate), and salts of poly (methacrylic acid). Porogens can include benzyl alcohol, cyclohexane, and toluene, among others.
The method can be performed ex vivo or in vivo, depending on the specific application. The patent also claims the use of this method for the treatment of degenerative diseases, such as Alzheimer's disease, macular degeneration, osteoarthritis, atherosclerosis, heart disease, or kidney failure.
In summary, this patent describes a method for removing advanced glycation end products from bodily fluids using a specific sorbent material. The method has potential applications in the treatment of degenerative diseases.
To know more about GlobalData’s detailed insights on CytoSorbents, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
